YOUR PATIENTS TRUST YOU

Your recommendation is the strongest predictor of patients getting vaccinated1

HOW TO DISCUSS SHINGLES PREVENTION WITH YOUR PATIENTS ≥50 YEARS OLD

Shingles: Painful and disruptive

Shingles is a blistering rash that can be excruciatingly painful, usually lasting 7 to 10 days, and can disrupt everyday activities such as work, family time, and sleep.2-4

Risk: Age and comorbidities

Shingles risk sharply increases starting at 50 years old.2

In addition to age, certain chronic conditions have been associated with an increased risk of shingles.5

SHINGRIX: Outstanding efficacy

SHINGRIX, administered as a 2-dose series, was proven more than 90% effective in preventing shingles in people 50 years and older.6,*

The most common side effects are pain, redness, and swelling at the injection site, muscle pain, tiredness, headache, shivering, fever, and upset stomach.

  • *

    Data from the phase 3 ZOE-50 (≥50 years old) trial (median follow-up period 3.1 years) and pooled data in individuals ≥70 years old from the phase 3 ZOE-50 and ZOE-70 trials (median follow-up period 4 years) in subjects who received 2 doses of SHINGRIX (n=7344 and 8250, respectively) or placebo (n=7415 and 8346, respectively). These populations represented the modified Total Vaccinated Cohort, defined as patients who received 2 doses (0 and 2 months) of either SHINGRIX or placebo and did not develop a confirmed case of herpes zoster within 1 month after the second dose.6,7

 

WHAT YOU NEED TO KNOW ABOUT SHINGLES

Shingles is a painful blistering rash caused by the reactivation of the latent varicella zoster virus (VZV).2

  • 99.5% of people ≥50 years old are infected with VZV2,8
  • In 1 in 3 people, the dormant virus reactivates in their lifetime and causes shingles2
  • Starting at 50 YEARS OLD, shingles risk SHARPLY INCREASES2
  • Additional risk factors:
    DIABETES, ASTHMA, COPD, CHRONIC KIDNEY DISEASE, or CARDIOVASCULAR CONDITIONS have been associated with an increased risk of shingles5,†

RECOGNIZING THE RISK FACTORS CAN HELP YOU MAKE A PERSONALIZED RECOMMENDATION TO YOUR PATIENTS

  • †Cardiovascular conditions include heart disease, heart failure, hypertension, hyperlipidemia, stroke, atrial fibrillation/flutter, and other cardiovascular disease.
  • COPD=chronic obstructive pulmonary disease.

HELP YOUR PATIENTS COMPLETE THE 2-DOSE SERIES

Encourage them to book their second appointment at your office or a pharmacy by visiting

SCHEDULESHINGRIX.COM

SHINGRIX is $0 for most patients ≥50 years old9,10,‡

  • 98% of commercially insured patients pay $0 for SHINGRIX9,§
  • Medicare Part D patients can get SHINGRIX for $0 through their pharmacy10
SEE COST AND COVERAGE INFORMATION
  • ‡Coverage and cost may vary and are subject to change without notice. Reimbursement decisions are made by individual insurance plans.
  • § Source: Based on IQVIA data of paid 2023 SHINGRIX claims.
SHINGRIX Strong Recommendation Guide

Share the Strong Recommendation Guide with others in your practice

This guide provides the top 3 talking points for you to share with patients.

Download
Download PDF Root Path

ADMINISTER OR SCHEDULE TODAY. RECOMMEND SHINGRIX.

Indication & Important Safety Info

Indication

Important Safety Information

Indication

SHINGRIX is a vaccine indicated for prevention of herpes zoster (HZ) (shingles):

  • in adults aged 50 years and older.
  • in adults aged 18 years and older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Important Safety Information

  • SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
  • Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
  • In a postmarketing observational study, an increased risk of Guillain-Barré syndrome was observed during the 42 days following vaccination with SHINGRIX
  • Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
  • Solicited local adverse reactions reported in individuals aged 50 years and older were pain (78%), redness (38%), and swelling (26%)
  • Solicited general adverse reactions reported in individuals aged 50 years and older were myalgia (45%), fatigue (45%), headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%)  
  • Solicited local adverse reactions reported in autologous hematopoietic stem cell transplant recipients (aged 18 to 49 and ≥50 years of age) were pain (88% and 83%), redness (30% and 35%), and swelling (21% and 18%)  
  • Solicited general adverse reactions reported in autologous hematopoietic stem cell transplant recipients (aged 18 to 49 and ≥50 years of age) were fatigue (64% and 54%), myalgia (58% and 52%), headache (44% and 30%), gastrointestinal symptoms (21% and 28%), shivering (31% and 25%), and fever (28% and 18%)
  • The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women
  • It is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion
  • Vaccination with SHINGRIX may not result in protection of all vaccine recipients

 

Please see full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact GSK at gsk.public.reportum.com or
1-888-825-5249, or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

References

  1. Adult immunization standards. Centers for Disease Control and Prevention. Reviewed August 9, 2024. Accessed July 1, 2025. https://www.cdc.gov/vaccines-adults/hcp/imz-standards/
  2. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-5):1-30.
  3. Curran D, Matthews S, Boutry C, Lecrenier N, Cunningham AL, Schmader K. Natural history of herpes zoster in the placebo groups of three randomized phase III clinical trials. Infect Dis Ther. 2022;11(6):2265-2277.
  4. Shingles symptoms and complications. Centers for Disease Control and Prevention. Reviewed April 19, 2024. Accessed July 1, 2025. https://www.cdc.gov/shingles/signs-symptoms/index.html
  5. Marra F, Parhar K, Huang B, Vadlamudi N. Risk factors for herpes zoster infection: a meta-analysis. Open Forum Infect Dis. 2020;7(1):1-8.
  6. Prescribing Information for SHINGRIX.
  7. Data on file. Study 113077 (NCT01165229). GSK Study Register. Accessed July 1, 2025. Study entry at: https://www.gsk-studyregister.com/en/trial-details/?id=113077
  8. Kilgore PE, Kruszon-Moran D, Seward JF, et al. Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol. 2003;70(suppl 1):S111-S118.
  9. Data on file, GSK.
  10. Wreschnig LA. Selected Health Provisions of the Inflation Reduction Act. Congressional Research Service. 2022;1-3. Accessed July 1, 2025. https://crsreports.congress.gov/product/pdf/IF/IF12203

    Questions About SHINGRIX?

    Call: 1-800-772-9292

    Available Monday - Friday

    8:30 am to 5:30 pm ET